早期直肠肿瘤内镜黏膜下剥离术对比经肛微创手术的随机试验
这项多中心随机非劣效试验比较了ESD与TAMIS治疗早期直肠肿瘤,ESD在12个月复发方面非劣于TAMIS,且住院时间更短、技术成功率更高、费用更低。
要点
- ESD在12个月局部复发方面非劣于TAMIS
- ESD住院时间更短(1天 vs 2天)
- ESD技术成功率更高(100% vs 88.9%,符合方案分析)
核心结论
- ESD在早期直肠肿瘤局部切除的12个月复发方面非劣于TAMIS,两者安全性良好,ESD技术限制更少、手术成功率更高、住院更短、费用更低且患者接受度更高。
研究设计与样本
- 多中心、随机、开放标签、非劣效试验,在3个西班牙三级中心开展。
主要发现
- 185例评估患者中73例随机(TAMIS组34例,ESD组39例),66例(90.4%)完成随访。
- TAMIS组2例出现局部复发,ESD组无复发。
- 12个月复发风险差在意向性分析中为-6.7%(90%CI -14.2至0.8),符合方案分析中为-8.3%(90%CI -17.6至0.9)。
- ESD住院时间更短(1天 vs 2天),符合方案分析中技术成功率更高(100% vs 88.9%)。
- 总体并发症无显著差异;TAMIS估计总费用€11289.27,ESD为€6167.14。
关键数值与推荐
- 纳入标准:无蒂早期直肠肿瘤,大小>20mm,≤cT1N0。
- 主要结局非劣效界值为10%。
- 112例研究外病例中108例(96.4%)成功接受ESD治疗。
临床怎么用
- 对于无蒂、>20mm且≤cT1N0的早期直肠肿瘤,ESD可作为TAMIS的非劣效替代方案,且具有住院更短、费用更低的优势。
- 解读结果时需考虑较宽的非劣效界值、有限样本量及缺乏多重性校正。
局限性
- 非劣效界值较宽(10%)。
- 样本量有限(73例随机)。
- 未进行多重性校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The optimal approach for the local resection of early rectal neoplasms (ERNs) remains debated, with limited data comparing transanal minimally invasive surgery (TAMIS) and endoscopic submucosal dissection (ESD). METHODS: A multicenter, randomized, open-label, noninferiority trial was conducted in 3 Spanish tertiary centers. Patients with nonpedunculated ERNs >20 mm and ≤cT1N0 were randomized to TAMIS or ESD. The primary outcome was 12-month recurrence (noninferiority margin, 10%). Secondary outcomes included technical success, en bloc, R0, and curative resection rates, procedure time, hospital stay, complications, and costs. Analyses followed intention-to-treat and per-protocol (PP) principles. RESULTS: Of 185 evaluated patients, 73 were randomized (34 TAMIS, 39 ESD) and 66 (90.4%) completed follow-up. Local recurrence occurred in 2 TAMIS patients and none in ESD. The 12-month recurrence risk difference was -6.7% (90% confidence interval, -14.2 to 0.8) in intention-to-treat and -8.3% (90% confidence interval, -17.6 to 0.9) in PP analysis. ESD demonstrated shorter hospital stays (1 vs 2 days) and higher technical success (100% vs 88.9%; PP). No significant differences were observed in overall complications. Estimated overall costs were €11,289.27 for TAMIS vs €6167.14 for ESD. Of the 112 off-study cases, 108 (96.4%) were successfully treated with ESD. CONCLUSIONS: ESD appears to be noninferior to TAMIS for local resection of ERNs regarding 12-month recurrence. Both show favorable safety profiles. ESD was associated with fewer technical constraints, higher procedural success, shorter hospitalization, lower cost, and greater patient acceptance. These results should be interpreted considering the wide noninferiority margin, limited sample size, and absence of multiplicity adjustment. (ClinicalTrials.gov, Number: NCT03959839).
引用
- de Frutos Rosa D, Alonso Sebastián I, Barquero Declara D, et al. A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study. Gastroenterology. 2025. PMID: 40749854. doi:10.1053/j.gastro.2025.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。